BIOLOGICAL RATIONALE FOR PLANNING THE TREATMENT OF BREAST CANCER
- Authors: Semlglazov V.1, Semlglazov V.2, Paltuyev R.1, Semiglazova T.1, Dashyan G.1
-
Affiliations:
- NN. Petrov Oncology Research Institute
- 2Acad. I.P. Pavlov Saint Petersburg Medical University
- Issue: Vol 23, No 11 (2012)
- Pages: 2-4
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115520
- ID: 115520
Cite item
Abstract
Keywords
Full Text
About the authors
V. Semlglazov
NN. Petrov Oncology Research Institute
Email: vsemiglazov@mail.ru
Professor MD, Corresponding Member of the Russian Academy of Medical Sciences Saint Petersburg
V. Semlglazov
2Acad. I.P. Pavlov Saint Petersburg Medical UniversityProfessor MD Saint Petersburg
R. Paltuyev
NN. Petrov Oncology Research InstituteCandidate of Medical Sciences Saint Petersburg
T. Semiglazova
NN. Petrov Oncology Research InstituteCandidate of Medical Sciences Saint Petersburg
G. Dashyan
NN. Petrov Oncology Research InstituteCandidate of Medical Sciences Saint Petersburg
References
- Cheang M., Chia S., Voduc D. et al. Ki67 index, HER2 status, and prognosis of patients with luminal В breast cancer // J. Natl. Cancer. Inst. - 2009; 101: 736-50.
- Hammond M., Hayes D., Wolff A. Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer // J. Clin. Oncol. - 2011; 29: 1152-62.
- Perou C., Sorlie T., Eisen M. et al. Molecular portraits of human breast tumours // Nature. - 2000; 406: 747-52.
- Piccart-Gebhart M., Procter M., Leyland-Jones В. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer // N. Engl. J. Med. - 2005; 353: 1659-72.
- Romond E., Perez E., Bryant J. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer // N. Engl. J. Med. -2005; 353: 1673-84.
- Viale G., Regan M., Mastropasqua M. et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for nodenegative breast cancer // J. Natl. Cancer. Inst. - 2008; 100: 207-12.